TET2截短突变预示着母细胞性浆细胞样树突状细胞肿瘤的预后更差。 - Suppr

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.

作者信息

Beird Hannah, Yin C Cameron, Khoury Joseph D, Pierce Sherry, Abbas Hussein A, Zhao Li, Skwarska Anna, Qazilbash Muzaffar, Konopleva Marina, Futreal P Andrew, Pemmaraju Naveen

机构信息

Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.

Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

Blood Adv. 2023 May 23;7(10):2000-2003. doi: 10.1182/bloodadvances.2022007879.

DOI:10.1182/bloodadvances.2022007879

PMID:36689729

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10188632/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b83a/10188632/372908003734/BLOODA_ADV-2022-007879-gr1.jpg

相似文献

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.

Blood Adv. 2023 May 23;7(10):2000-2003. doi: 10.1182/bloodadvances.2022007879.

Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.

Leukemia. 2021 Nov;35(11):3299-3303. doi: 10.1038/s41375-021-01228-y. Epub 2021 Apr 8.

Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics.

Hematol Oncol Clin North Am. 2020 Jun;34(3):511-521. doi: 10.1016/j.hoc.2020.01.002. Epub 2020 Mar 4.

Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.

J Int Med Res. 2021 Feb;49(2):300060520982667. doi: 10.1177/0300060520982667.

Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP.

Am J Hematol. 2020 Feb;95(2):E31-E34. doi: 10.1002/ajh.25675. Epub 2019 Dec 4.

Blastic Plasmacytoid Dendritic Cell Neoplasm: The Dermatologist's Perspective.

Hematol Oncol Clin North Am. 2020 Jun;34(3):501-509. doi: 10.1016/j.hoc.2020.01.001. Epub 2020 Mar 20.

New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis.

J Thromb Haemost. 2010 May;8(5):1142-4. doi: 10.1111/j.1538-7836.2010.03810.x. Epub 2010 Feb 12.

TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.

Am J Hematol. 2013 Dec;88(12):1055-61. doi: 10.1002/ajh.23567. Epub 2013 Sep 30.

Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm.

Haematologica. 2009 Feb;94(2):285-8. doi: 10.3324/haematol.13855. Epub 2008 Dec 9.

TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.

Br J Haematol. 2011 May;153(3):413-6. doi: 10.1111/j.1365-2141.2010.08556.x. Epub 2011 Jan 31.

引用本文的文献

Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.

Oncotarget. 2025 Jun 17;16:495-507. doi: 10.18632/oncotarget.28742.

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN.

Blood Neoplasia. 2025 Mar 3;2(2):100086. doi: 10.1016/j.bneo.2025.100086. eCollection 2025 May.

Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.

Clin Pathol. 2024 Dec 16;17:2632010X241304564. doi: 10.1177/2632010X241304564. eCollection 2024 Jan-Dec.

BPDCN: state of the art.

Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):279-286. doi: 10.1182/hematology.2024000553.

Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival.

Blood Adv. 2024 Jun 11;8(11):2803-2812. doi: 10.1182/bloodadvances.2024012797.

Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis.

Blood Cancer J. 2023 Aug 9;13(1):119. doi: 10.1038/s41408-023-00893-9.

本文引用的文献

The burden of rare protein-truncating genetic variants on human lifespan.

Nat Aging. 2022 Apr;2(4):289-294. doi: 10.1038/s43587-022-00182-3. Epub 2022 Mar 3.

Biallelic mutations and canonical mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature.

EJHaem. 2023 Jan 4;4(1):236-240. doi: 10.1002/jha2.617. eCollection 2023 Feb.

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.

J Clin Oncol. 2022 Sep 10;40(26):3032-3036. doi: 10.1200/JCO.22.00034. Epub 2022 Jul 12.

Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.

Leukemia. 2022 May;36(5):1343-1350. doi: 10.1038/s41375-022-01538-9. Epub 2022 Mar 12.

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.

Blood Adv. 2022 May 24;6(10):3027-3035. doi: 10.1182/bloodadvances.2021006645.

Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Cancers (Basel). 2021 Nov 23;13(23):5888. doi: 10.3390/cancers13235888.

Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.

Am J Hematol. 2022 Feb 1;97(2):E62-E67. doi: 10.1002/ajh.26417. Epub 2021 Nov 29.

Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Bone Marrow Transplant. 2022 Jan;57(1):51-56. doi: 10.1038/s41409-021-01478-5. Epub 2021 Oct 11.

Sex-Biased Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.

Cancer Discov. 2022 Feb;12(2):522-541. doi: 10.1158/2159-8290.CD-20-1513. Epub 2021 Oct 6.

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm.

Blood. 2021 Oct 14;138(15):1373-1377. doi: 10.1182/blood.2021011817.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.

作者信息

Beird Hannah, Yin C Cameron, Khoury Joseph D, Pierce Sherry, Abbas Hussein A, Zhao Li, Skwarska Anna, Qazilbash Muzaffar, Konopleva Marina, Futreal P Andrew, Pemmaraju Naveen

机构信息

Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.

Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

Blood Adv. 2023 May 23;7(10):2000-2003. doi: 10.1182/bloodadvances.2022007879.

DOI:10.1182/bloodadvances.2022007879

PMID:36689729

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10188632/

Abstract

摘要

相似文献

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.

Blood Adv. 2023 May 23;7(10):2000-2003. doi: 10.1182/bloodadvances.2022007879.

Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.

Leukemia. 2021 Nov;35(11):3299-3303. doi: 10.1038/s41375-021-01228-y. Epub 2021 Apr 8.

Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics.

Hematol Oncol Clin North Am. 2020 Jun;34(3):511-521. doi: 10.1016/j.hoc.2020.01.002. Epub 2020 Mar 4.

Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.

J Int Med Res. 2021 Feb;49(2):300060520982667. doi: 10.1177/0300060520982667.

Am J Hematol. 2020 Feb;95(2):E31-E34. doi: 10.1002/ajh.25675. Epub 2019 Dec 4.

Blastic Plasmacytoid Dendritic Cell Neoplasm: The Dermatologist's Perspective.

Hematol Oncol Clin North Am. 2020 Jun;34(3):501-509. doi: 10.1016/j.hoc.2020.01.001. Epub 2020 Mar 20.

New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis.

J Thromb Haemost. 2010 May;8(5):1142-4. doi: 10.1111/j.1538-7836.2010.03810.x. Epub 2010 Feb 12.

TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.

Am J Hematol. 2013 Dec;88(12):1055-61. doi: 10.1002/ajh.23567. Epub 2013 Sep 30.

Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm.

Haematologica. 2009 Feb;94(2):285-8. doi: 10.3324/haematol.13855. Epub 2008 Dec 9.

TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.

Br J Haematol. 2011 May;153(3):413-6. doi: 10.1111/j.1365-2141.2010.08556.x. Epub 2011 Jan 31.

引用本文的文献

Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.

Oncotarget. 2025 Jun 17;16:495-507. doi: 10.18632/oncotarget.28742.

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN.

Blood Neoplasia. 2025 Mar 3;2(2):100086. doi: 10.1016/j.bneo.2025.100086. eCollection 2025 May.

Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.

Clin Pathol. 2024 Dec 16;17:2632010X241304564. doi: 10.1177/2632010X241304564. eCollection 2024 Jan-Dec.

BPDCN: state of the art.

Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):279-286. doi: 10.1182/hematology.2024000553.

Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival.

Blood Adv. 2024 Jun 11;8(11):2803-2812. doi: 10.1182/bloodadvances.2024012797.

Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis.

Blood Cancer J. 2023 Aug 9;13(1):119. doi: 10.1038/s41408-023-00893-9.

本文引用的文献

The burden of rare protein-truncating genetic variants on human lifespan.

Nat Aging. 2022 Apr;2(4):289-294. doi: 10.1038/s43587-022-00182-3. Epub 2022 Mar 3.

Biallelic mutations and canonical mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature.

EJHaem. 2023 Jan 4;4(1):236-240. doi: 10.1002/jha2.617. eCollection 2023 Feb.

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.

J Clin Oncol. 2022 Sep 10;40(26):3032-3036. doi: 10.1200/JCO.22.00034. Epub 2022 Jul 12.

Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.

Leukemia. 2022 May;36(5):1343-1350. doi: 10.1038/s41375-022-01538-9. Epub 2022 Mar 12.

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.

Blood Adv. 2022 May 24;6(10):3027-3035. doi: 10.1182/bloodadvances.2021006645.

Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Cancers (Basel). 2021 Nov 23;13(23):5888. doi: 10.3390/cancers13235888.

Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.

Am J Hematol. 2022 Feb 1;97(2):E62-E67. doi: 10.1002/ajh.26417. Epub 2021 Nov 29.

Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Bone Marrow Transplant. 2022 Jan;57(1):51-56. doi: 10.1038/s41409-021-01478-5. Epub 2021 Oct 11.

Sex-Biased Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.

Cancer Discov. 2022 Feb;12(2):522-541. doi: 10.1158/2159-8290.CD-20-1513. Epub 2021 Oct 6.

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm.

Blood. 2021 Oct 14;138(15):1373-1377. doi: 10.1182/blood.2021011817.

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献